PARIS and CAMBRIDGE, Mass., May 15, 2024 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – the ''Company''), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, announced today that it will report its financial and operational results for the first quarter of 2024 on May 22, 2024, before the US and EU markets open. This release will be followed by a conference call and webcast on May 22, 2024 at 8:00 am EDT ...

PARIS and CAMBRIDGE, Mass., May 14, 2024 (GLOBE NEWSWIRE) -- NANOBIOTIX (NASDAQ:NBTX), a late-clinical stage biotechnology company pioneering nanoparticle-based therapeutic approaches to expand treatment possibilities for patients with cancer and other major diseases, today announced that the U.S. Food and Drug Administration ("US FDA") issued a Study May Proceed Letter for a randomized Phase 2 study evaluating NBTXR3 for the treatment of patients with stage 3, unresectable non-small cell lung cancer ("NSCL ...

Nanobiotix S.A. (NASDAQ:NBTX) Q4 2023 Earnings Conference Call April 25, 2024 8:00 AM ET Company Participants Craig West - Senior Vice President, Investor Relations Laurent Levy - Co-Founder and Chief Executive Officer Bart Van Rhijn - Chief Financial Officer Conference Call Participants Dylan Drakes - Leerink Partners Lucy Codrington - Jefferies Swayampakula Ramakanth - H.C. Wainwright. Clemence Thiers - Stifel Elliott Bosco - UBS Operator Good day and welcome to the Nanobiotix Business Update and Full-Yea ...

EXHIBIT 99.1 NANOBIOTIX Provides Business Update and Reports Full Year 2023 Financial Results Conference call and webcast scheduled for April 25, 2024 at 8:00 A.M. EDT / 2:00 P.M. CEST PARIS and CAMBRIDGE, Mass., April 24, 2024 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO - NASDAQ: NBTX - the "Company"), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, provided an update on operational progress and reported financia ...

Global licensing, co-development, and commercialization agreement with Janssen Pharmaceutica NV ("Janssen") expands worldwide potential of novel radioenhancer NBTXR3Prolonged survival in Study 102 reinforces pivotal NANORAY-312 trial design in head and neck cancer; initial efficacy and favorable safety profile supports potential of NBTXR3 in pancreatic cancer; determined RP2D for MD Anderson lung studyMultiple clinical readouts expected in 2024 including immunotherapy combination data from Study 1100, and d ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ________________________ FORM 20-F ________________________ (Mark One) o REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 for the fiscal year ended December 31, 2023 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 for the transition period from __________ to _ ...

Laurent Levy Hi. Thank you for taking my question. I had one for the pancreatic cancer study. How comparable are the baseline characteristics of the patients into previous MD studies? And the patients in the ongoing Phase 1, for instance, in terms of level of CA19-9 at diagnosis? And could you give us the amplitude of reduction of that biomarker levels observed in your study? the RP2D. So, the enrollment continues to be good in this trial. It's just slightly delayed versus what was initially planned. But al ...

• Cash balance as of September 30, 2023: €38.7 million • Closing of recent financing result(ed) in gross proceeds of €50.9 million • EIB cash covenant removed • This excludes any further dilutive (incl. use of equity line) or non-dilutive financing, and includes a first de- risked milestones from NBTXR3 collaboration • Cash Runway is expected to extend to end of Q2 25 upon completion of remaining amount of €4.6 million of €23.7 million ($25 million) second tranche commitment of JJDC, subject to closing cond ...

Nanobiotix S.A. (NASDAQ:NBTX) Q2 2023 Earnings Conference Call September 27, 2023 8:00 AM ET Company Participants Craig West - SVP, IR Laurent Levy - Co-Founder & CEO Bart Van Rhijn - CFO Conference Call Participants Lucy Codrington - Jefferies Swayampakula Ramakanth - H.C. Wainwright Operator Good day, and thank you for standing by. Welcome to the Nanobiotix Business Update and First Half 2023 Financial Results Conference Call. At this time, all participants are in a listen-only mode. After the speakerÂ's ...

Nanobiotix S.A. (NASDAQ:NBTX) Q4 2022 Results Conference Call April 25, 2023 8:00 AM ET Company Participants Craig West - SVP, IR Laurent Levy - Co-Founder and CEO Bart Van Rhijn - CFO Conference Call Participants Jonathan Miller - Evercore ISI Elliott Bosco - UBS Swayampakula Ramakanth - H.C. Wainwright Clément Bassat - BNP Paribas Operator Good day, and thank you for standing by. Welcome to the Nanobiotix business update and full-year 2022 financial results conference call. A slide presentation accompanyi ...